Drugs in R & D

, Volume 3, Issue 1, pp 25–27 | Cite as

Aripiprazole

Abilitat®, OPC 14597
Adis R&D Profile
  • 7 Downloads

Keywords

Schizophrenia Haloperidol Aripiprazole Psychotic Disorder Extrapyramidal Symptom 

References

  1. 1.
    Mallikaarjun S, Salazar DE, Bramer SL. The pharmacokinetics, tolerability, and safety of aripirazole following single and mutiple oral dose administration. International Journal of Neuropsychopharmacology. 3 (Suppl 1): 123–124, Jul 2000. USA. [English]Google Scholar
  2. 2.
    Toru M, Miura S, Kudo Y. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Neuropsychopharmacology. 10 (Suppl Part 1): 122, May 1994. Japan. [English]Google Scholar
  3. 3.
    Toru M, Miura S. Late phase II study of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. European Neuropsychopharmacology. 6 (Suppl 3): 18, Jun 1996. Japan. [English]CrossRefGoogle Scholar
  4. 4.
    Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. International Journal of Neuropsychopharmacology. 3 (Suppl 1): 124 (plus poster), Jul 2000. USA. [English]Google Scholar
  5. 5.
    Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. European Journal of Pharmacology. 321: 105–111, 19 Feb 1997 Japan. [English]PubMedCrossRefGoogle Scholar
  6. 6.
    Uwahodo Y, Kikuchi T, Tottori K, et al. Pharmacological profile of OPC-14597, a novel anti-psychotic drug (2): weak extrapyramidal side effects. Japanese Journal of Pharmacology. 67 (Suppl I): 144, 1995. Japan. [English]Google Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations